BR112013008974A2 - Composição farmacêutica, processo para fabricar uma composição farmacêutica e uso de uma composição farmacêutica - Google Patents
Composição farmacêutica, processo para fabricar uma composição farmacêutica e uso de uma composição farmacêuticaInfo
- Publication number
- BR112013008974A2 BR112013008974A2 BR112013008974A BR112013008974A BR112013008974A2 BR 112013008974 A2 BR112013008974 A2 BR 112013008974A2 BR 112013008974 A BR112013008974 A BR 112013008974A BR 112013008974 A BR112013008974 A BR 112013008974A BR 112013008974 A2 BR112013008974 A2 BR 112013008974A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- manufacturing
- indacaterol
- ciclesonide
- formoterol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 abstract 1
- 229940124748 beta 2 agonist Drugs 0.000 abstract 1
- 229960003728 ciclesonide Drugs 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960002714 fluticasone Drugs 0.000 abstract 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 abstract 1
- 229960002848 formoterol Drugs 0.000 abstract 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004078 indacaterol Drugs 0.000 abstract 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2847MU2010 | 2010-10-12 | ||
| IN69MU2011 | 2011-01-10 | ||
| IN106MU2011 | 2011-01-12 | ||
| IN135MU2011 | 2011-01-14 | ||
| IN143MU2011 | 2011-01-17 | ||
| PCT/GB2011/001115 WO2012049444A1 (en) | 2010-10-12 | 2011-07-25 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013008974A2 true BR112013008974A2 (pt) | 2023-12-19 |
Family
ID=44651863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013008974A BR112013008974A2 (pt) | 2010-10-12 | 2011-07-25 | Composição farmacêutica, processo para fabricar uma composição farmacêutica e uso de uma composição farmacêutica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10179139B2 (enExample) |
| EP (1) | EP2627325A1 (enExample) |
| JP (2) | JP2013542940A (enExample) |
| KR (2) | KR20140025308A (enExample) |
| CN (2) | CN107998109A (enExample) |
| AU (1) | AU2011315315B2 (enExample) |
| BR (1) | BR112013008974A2 (enExample) |
| CA (1) | CA2814445A1 (enExample) |
| MX (1) | MX2013004137A (enExample) |
| NZ (1) | NZ609358A (enExample) |
| RU (1) | RU2642624C2 (enExample) |
| WO (1) | WO2012049444A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130274232A1 (en) | 2010-07-16 | 2013-10-17 | Cipla Limited | Pharmaceutical Compositions |
| KR20140025308A (ko) | 2010-10-12 | 2014-03-04 | 시플라 리미티드 | 약학 조성물 |
| CN103784420A (zh) * | 2014-02-18 | 2014-05-14 | 青岛市城阳区人民医院 | 马来酸茚达特罗液体制剂及其制备方法 |
| US20170189329A1 (en) | 2014-07-29 | 2017-07-06 | 3M Innovative Properties Company | Method of preparing a pharmaceutical composition |
| AU2015393953B2 (en) * | 2015-05-01 | 2021-09-02 | Board Of Regents, The University Of Texas System | Multidrug brittle matrix compositions |
| ES2826562T3 (es) * | 2015-05-18 | 2021-05-18 | Glenmark Specialty Sa | Solución para inhalación de tiotropio por nebulizador |
| JP6781832B2 (ja) * | 2016-09-19 | 2020-11-04 | メキシケム フロー エセ・ア・デ・セ・ヴェ | 医薬組成物 |
| GB2554090A (en) * | 2016-09-19 | 2018-03-28 | Mexichem Fluor Sa De Cv | Pharmaceutical compound |
| EP3922240B1 (en) * | 2016-09-19 | 2023-06-21 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising tiotropium bromide |
| TR201712424A2 (tr) * | 2017-08-21 | 2019-03-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Kuru toz i̇nhalasyon bi̇leşi̇mleri̇ |
| WO2019142214A1 (en) * | 2018-01-19 | 2019-07-25 | Cipla Limited | Pharmaceutical composition comprising tiotropium for inhalation |
| EP3745236A4 (en) | 2018-01-24 | 2021-03-24 | Sony Corporation | INFORMATION PROCESSING DEVICE AND INFORMATION PROCESSING METHOD |
| EA202092976A1 (ru) * | 2018-06-04 | 2021-03-16 | Люпин Инк. | Устойчивые фармацевтические композиции для дозированных ингаляторов под давлением |
| WO2020105012A1 (en) * | 2018-11-22 | 2020-05-28 | Glenmark Specialty S.A. | Sterile compositions of indacaterol suitable for nebulization |
| US20200215051A1 (en) * | 2019-01-03 | 2020-07-09 | Glenmark Specialty S.A. | Nebulization composition comprising tiotropium and indacaterol |
| CN113853197B (zh) * | 2019-10-11 | 2022-08-30 | 四川海思科制药有限公司 | 一种吸入溶液药物组合物及其制备方法 |
| CN110840864B (zh) * | 2019-12-20 | 2022-02-22 | 广州健康元呼吸药物工程技术有限公司 | 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品 |
| CN111467498A (zh) * | 2020-05-14 | 2020-07-31 | 王兆霖 | 药物组合物制剂 |
| WO2022073009A1 (en) * | 2020-09-29 | 2022-04-07 | iPharma Labs, Inc. | Liquid formulations of indacaterol |
| EP4611733A1 (en) * | 2022-11-03 | 2025-09-10 | Dana-Farber Cancer Institute, Inc. | Methods of treating anemia using formoterol or a pharmaceutically acceptable salt thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9700135D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| US6120752A (en) * | 1997-05-21 | 2000-09-19 | 3M Innovative Properties Company | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
| US5879715A (en) | 1997-09-02 | 1999-03-09 | Ceramem Corporation | Process and system for production of inorganic nanoparticles |
| GB9903759D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| GB0009591D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medical combinations |
| EP1277787A4 (en) | 2000-04-28 | 2009-11-11 | Mitsubishi Tanabe Pharma Corp | METHOD FOR PRODUCING MICROSPHERES |
| FI20002216A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit astman hoitoon |
| GB0029562D0 (en) | 2000-12-04 | 2001-01-17 | Novartis Ag | Organic compounds |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| JP2005523268A (ja) * | 2002-02-04 | 2005-08-04 | グラクソ グループ リミテッド | グルココルチコイドおよびβ２−アドレナリン受容体アゴニストを含む吸入用製剤 |
| CA2496699C (en) * | 2002-08-29 | 2012-07-17 | Cipla Ltd. | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
| AU2003263717A1 (en) | 2002-09-25 | 2004-04-19 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
| AU2003293833B2 (en) * | 2002-12-12 | 2009-10-01 | Covis Pharma B.V. | Combination medicament |
| US6962006B2 (en) | 2002-12-19 | 2005-11-08 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
| CA2528479A1 (en) | 2003-06-13 | 2004-12-23 | Altana Pharma Ag | Formoterol and ciclesonide combination |
| SE527190C2 (sv) | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid |
| SE527200C2 (sv) | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av formaterol och fluticason |
| US20050258288A1 (en) | 2003-11-26 | 2005-11-24 | E. I. Du Pont De Nemours And Company | High pressure media milling system and process of forming particles |
| US20060008498A1 (en) | 2004-07-12 | 2006-01-12 | Chen Tzer-Fen D | Nano-particle production |
| DE102004056578A1 (de) | 2004-11-23 | 2006-05-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Formoterol und ein Steroid |
| WO2006073154A1 (ja) | 2005-01-07 | 2006-07-13 | Eisai R&D Management Co., Ltd. | 医薬組成物及びその製造方法 |
| MX2007012084A (es) | 2005-03-30 | 2007-11-21 | Schering Corp | Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada. |
| GB0511066D0 (en) * | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| DE602006008665D1 (de) | 2005-12-21 | 2009-10-01 | Meda Pharma Gmbh & Co Kg | Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten |
| US20100172994A1 (en) | 2006-11-22 | 2010-07-08 | University Of Florida Research Foundation, Inc. | Nanoparticles for Protection of Cells from Oxidative Stress |
| EP2124915A2 (en) | 2007-02-19 | 2009-12-02 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
| TWI405590B (zh) | 2007-04-06 | 2013-08-21 | Activus Pharma Co Ltd | 微粉碎化有機化合物粒子之製法 |
| JP5109515B2 (ja) | 2007-07-17 | 2012-12-26 | 株式会社ジェイテクト | 摺動式トリポード形等速ジョイント |
| KR20100063116A (ko) * | 2007-09-12 | 2010-06-10 | 글락소 그룹 리미티드 | 치료제들의 복합제 |
| DE102007054885A1 (de) | 2007-11-15 | 2009-05-20 | Evonik Degussa Gmbh | Verfahren zur Fraktionierung oxidischer Nanopartikel durch Querstrom-Membranfiltration |
| FR2929136B1 (fr) | 2008-03-25 | 2011-11-11 | Sprainnov | Procede et tete de pulverisation, procede et tour associes pour fabriquer un produit pulverulent |
| EP2321023B1 (en) | 2008-07-18 | 2016-06-15 | Prosonix Limited | Process for improving crystallinity of fluticasone particles |
| CN101474191B (zh) * | 2009-01-21 | 2011-03-23 | 李虎山 | 一种治疗哮喘和慢性阻塞性肺病的药物组合物 |
| US8668901B2 (en) * | 2009-02-04 | 2014-03-11 | Activaero Gmbh Research & Development | Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma |
| EP2221048A1 (en) * | 2009-02-18 | 2010-08-25 | Siegfried Generics International AG | Pharmaceutical composition for inhalation |
| CA2759109A1 (en) | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics |
| GB0918431D0 (en) | 2009-10-21 | 2009-12-09 | Prosonix Ltd | Process for improving crystallinity |
| KR20140025308A (ko) | 2010-10-12 | 2014-03-04 | 시플라 리미티드 | 약학 조성물 |
-
2011
- 2011-07-25 KR KR1020137012107A patent/KR20140025308A/ko not_active Ceased
- 2011-07-25 MX MX2013004137A patent/MX2013004137A/es unknown
- 2011-07-25 JP JP2013533267A patent/JP2013542940A/ja active Pending
- 2011-07-25 NZ NZ60935811A patent/NZ609358A/en not_active IP Right Cessation
- 2011-07-25 WO PCT/GB2011/001115 patent/WO2012049444A1/en not_active Ceased
- 2011-07-25 CA CA2814445A patent/CA2814445A1/en not_active Abandoned
- 2011-07-25 KR KR1020187006863A patent/KR20180028563A/ko not_active Ceased
- 2011-07-25 CN CN201711377918.8A patent/CN107998109A/zh active Pending
- 2011-07-25 EP EP11752315.9A patent/EP2627325A1/en not_active Ceased
- 2011-07-25 CN CN2011800597356A patent/CN103269694A/zh active Pending
- 2011-07-25 AU AU2011315315A patent/AU2011315315B2/en not_active Ceased
- 2011-07-25 RU RU2013119938A patent/RU2642624C2/ru not_active IP Right Cessation
- 2011-07-25 BR BR112013008974A patent/BR112013008974A2/pt not_active IP Right Cessation
- 2011-07-25 US US13/879,145 patent/US10179139B2/en active Active
-
2016
- 2016-10-06 JP JP2016197697A patent/JP2017039746A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20140147393A1 (en) | 2014-05-29 |
| CA2814445A1 (en) | 2012-04-19 |
| RU2642624C2 (ru) | 2018-01-25 |
| RU2013119938A (ru) | 2014-11-20 |
| NZ609358A (en) | 2015-04-24 |
| CN103269694A (zh) | 2013-08-28 |
| JP2013542940A (ja) | 2013-11-28 |
| KR20140025308A (ko) | 2014-03-04 |
| WO2012049444A1 (en) | 2012-04-19 |
| MX2013004137A (es) | 2013-07-29 |
| KR20180028563A (ko) | 2018-03-16 |
| AU2011315315A1 (en) | 2013-05-09 |
| CN107998109A (zh) | 2018-05-08 |
| US10179139B2 (en) | 2019-01-15 |
| JP2017039746A (ja) | 2017-02-23 |
| AU2011315315B2 (en) | 2016-08-18 |
| EP2627325A1 (en) | 2013-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013008974A2 (pt) | Composição farmacêutica, processo para fabricar uma composição farmacêutica e uso de uma composição farmacêutica | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| BR112012001353A2 (pt) | anel vaginal, e, métodos para fabricar um anel vaginal e para dispensar um ou mais ingredientes farmaceuticamente ativos | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| CL2013001942A1 (es) | Composicion de suministro de farmaco biodegradable que comprende a) un copolimero de tres bloques biodegradable, b) un copolimero de dos bloques biodegradable, y c) cuando menos un principio farmaceuticamente activo; metodo para su preparacion: y su uso. | |
| BR112013012587A2 (pt) | composição farmacêutica para administração nasal | |
| BR112015018092A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
| BR112015018094A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
| CL2013002033A1 (es) | Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar. | |
| BR112015018089A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
| CY1119798T1 (el) | Μορφη iv υδροχλωρικης ιβαμπραδινης | |
| EA201490760A1 (ru) | R(+)-n-метилпропаргиламиноиндан | |
| TR201000680A2 (tr) | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler | |
| BRPI1008227A8 (pt) | composição de glicocorticoide inalável para uso na terapia de um paciente que sofre de asma severa e sem controle. | |
| MX374944B (es) | Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. | |
| BRPI1008821A2 (pt) | Uso de uma fonte de dióxido de cloro | |
| BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| CL2011003327A1 (es) | Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales. | |
| WO2014153009A3 (en) | Thiosaccharide mucolytic agents | |
| NZ714288A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| WO2012162439A3 (en) | Compositions comprising fusidic acid and packages therefor | |
| CL2014003525A1 (es) | Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension. | |
| DOP2016000003A (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán | |
| CL2013003700A1 (es) | Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 9A, 10A, 11A E 12A ANUIDADES. |
|
| B25G | Requested change of headquarter approved |
Owner name: CIPLA LIMITED (IN) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2764 DE 26-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |